“RDA: better chemotherapy
management”
Investor Presentation
April 2013
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
1
Would you prefer
to know if your
chemotherapy is
working or not NOW
Would you like to endure
OR
© 2013 RNA Diagnostics Inc. All rights reserved.
26 weeks
of chemotherapy
side effects?
Confidential
2
Problem: Adverse Side Effects
 50% of breast cancer patients
receive chemotherapy
 75% of chemo patients derive
no long term benefit
 All patients suffer adverse side
effects
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
3
Solution:
RDA™ improved chemotherapy management
 First “Real Time” chemotherapy guidance tool
 Only prognostic test to measure response to
chemotherapy early in treatment
 Discovered in clinical trial (NCIC MA.22)
 Protected by broad patents
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
4
Benefits for Patients, Physicians and Payers
 For non responding patients, treatment can be altered quickly
 Significant reduction in adverse effects
 Switch to alternate treatment improves survival benefit
 Objective & useful tool for physicians
 Cost savings for healthcare payers ($20k - $60K / patient)
“RDA
holds the prospect of providing
oncologists with an extremely valuable method
for managing the chemotherapy of their breast
cancer patients”
Maureen E. Trudeau MD, FRCPC
Head, Division of Medical Oncology/Hematology, Sunnybrook
Health Sciences Centre, Head, Systemic Therapy Program,
Odette Cancer Centre, Toronto, Canada
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
5
Technology : RNA Disruption Assay (RDA™)
 National Cancer Institute of
Canada breast cancer trial
(MA.22)
 Clear discrimination between
responders and nonresponders
 RDA strongly correlates with
pathological complete
response (pCR) at end of
therapy
 Negative Predictive Value =
0.99
 False Negative 1%
© 2013 RNA Diagnostics Inc. All rights reserved.
RDA™ Performance
Characteristics
Confidential
6
RDA™ Clinical Scoring
RDA Score
Clinical Guidance
1
Patient is a non-responder, chemotherapy is not working.
Consider alternate approach
NPV 0.99 False Negative Rate of 0.01
2
Patient is a partial responder – chemotherapy should be continued
3
High level of RNA structural dysfunction – chemotherapy is
working. Patient 3x more likely to achieve pCR than untested
cohort
PPV 0.17
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
7
RDA: Clinical System
Chemotherapy selected
Raw data analysed by Rna DIAGNOSTICS
using proprietary algorithms.
Results transmitted to clinician
Chemotherapy infusion
RNA Disruption analysed at
Rna DIAGNOSTICS central lab
© 2013 RNA Diagnostics Inc. All rights reserved.
Breast tumour biopsy
Fine Needle Aspirate,
2 samples
Tumour RNA Fixative
Confidential
8
Management Team
Management
 CEO: Dr. Ken Pritzker, MD, FRCPC
 Former Chief Pathology & Lab Medicine, Mount Sinai Hospital, Toronto, Cancer diagnostics expert
 CSO: Dr. Amadeo Parissenti, PhD
 Cancer Research Scientist, Laurentian University
 VP Corporate Development: John Connolly, MBA
 Former partner at MDS Capital Corp. – 15 year Medtech entrepreneur
 CFO: John Jordan, MBA, CMA, CPA, ABV
 Financial executive, experienced working with high growth technology companies
Clinical Advisory Board
 Maureen Trudeau, MA, MD, FRCPC - Head , Medical Oncology, Sunnybrook
Health Sciences, Toronto, Canada
 Michael Untch, MD, PhD– Head , German Breast Group, Berlin, Germany
 Gunter von Minckwitz, MD, PhD – Chairman, German Breast Group, Frankfurt,
Germany
 Harry Bear, MD, PhD – Principal Investigator, NSABP, Virginia Commonwealth
University, USA
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
9
Market Opportunity in Breast Cancer
Developed World & BRIC Countries
Breast Cancer
New Case Incidence 2008
(Source: WHO GLOBOCAN 2008)
1,105,937
Total
379,738
BRIC
726,199
Total Developed World
425,147
Europe
205,446
USA & Canada
Japan & Australia
59,236
Total Addressable Market
$525M
350,000
$100 M
Size of Breast
Cancer Market
# of Patients per
yearin the
developed world
Sales Forecast
by 2018
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
10
Competition :Oncologists need better tools
Physical Exam
 Physical Exams
do not predict
efficacy
 Gene panels predict
 Imaging Over
probability of 10
estimates efficacy
year recurrence
 Too late to
 Don’t predict
impact clinical
efficacy
decision making
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
11
Sales Forecast
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
12
Rna Diagnostics Inc.





Unique solution for serious cancer problem
Large market - $500M in Breast Cancer
Strong IP and clinical data
Clinical trials underway
Rapid route to market
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
13
“RDA: better chemotherapy
management”
Investor Presentation
April 2013
© 2013 RNA Diagnostics Inc. All rights reserved.
Confidential
14